Companies Dominating the Neurotrophic Keratitis Landscape
- Dompe Farmaceutici SpA
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Oyster Point Pharma, Inc.
- Neuroptica, Inc.
- Recordati Rare Diseases
- KALA BIO
- ReGenTree, LLC
- BRIM Biotechnology, Inc.
- Bausch + Lomb Incorporated
- Oculis
- HLB Therapeutics
Browse Key Market Insights with Data Illustration:
In the News
- BRIM Biotechnology announced that the Board of Directors approved a seasoned equity offering that will issue 20 to 22.5 million shares of new stocks priced at 60-80 New Taiwan Dollars (~USD 2-2.67 per share). A total of ~USD 40-60 million will be raised to accelerate the development of several assets within its pipeline including the current phase 3 trial of lead asset BRM421 for dry eye disease (DED) in the US and speed up the enrollment of the phase 2 trial of BRM424 for neurotrophic keratitis (NK).
- Kala Pharmaceuticals, Inc. announced positive safety data from the first cohort of the CHASE (Corneal Healing After Secretome therapy) Phase 2b clinical trial evaluating KPI-012, a human mesenchymal stem cell secretome (MCS-S), for the treatment of persistent corneal epithelial defect (PCED). The first cohort enrolled two patients, treated with a high dose of KPI-012 (3 U/mL) four times per day (QID). Both patients successfully completed at least one week of dosing with no safety issues observed.
